FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
Imagine the furore if a Conservative government announced a scheme to shrink hospital waiting lists using financial incentives. First, they’d pay cash-strapped hospitals unlimited bonuses to kick patients off the lists. Then, they’d offer GPs cash to stop referring patients…
NHS clinicians will be supported to use groundbreaking AI tools that bulldoze bureaucracy and take notes to free up staff time and deliver better care to patients thanks to guidance published today.
Read more here.
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us